To Get Full Access :

Journavx

Journavx is a non‑opioid oral painkiller approved for adults with moderate‑to‑severe acute pain. It blocks sodium‑channel pain signals in the body, relieving pain without addiction risk.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Suzetrigine
  • Innovator :

    VERTEX PHARMACEUTICALS INC
  • Approval Date :

    30-Jan-25
  • NCE-1 Date :

    30-Jan-29
  • NCE Date :

    30-Jan-30
  • Dosage Form :

    Oral Tablet
  • Strength :

    50MG
  • Therapeutic Category :

    Analgesic
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    78
  • 2026 :

    291
  • 2027 :

    628
  • 2028 :

    1,082
  • 2029 :

    1,587
  • 2030 :

    2,133
  • 2031 :

    2,585
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?